| Document |
Document Title |
|
WO/2007/020888A1 |
A compound represented by the formula (I) or a salt thereof; and an agent for protecting a brain/neuronal cell or a therapeutic agent for sleep disorder comprising the compound or salt: wherein Z represents an oxygen or sulfur; R1 repres...
|
|
WO/2007/016208A2 |
The present invention provides substantially isolated ammonium salt of 1,2- benzisoxazole-3-methane sulfonic acid (BOS-NH4), which can be crystalline. The present invention also provides substantially chemically pure BOS-NH4, which is no...
|
|
WO/2007/016209A2 |
The present invention provides chemically pure sodium salt of 1,2-benzisoxazofe-3-methane-sulfonic acid, the sodium salt of 1,2-benzisoxazole-3-methane-sulfonic acid of high assay, or chemically pure sodium salt of 1,2-benzisoxazole-3-me...
|
|
WO/2007/015533A1 |
Disclosed is a novel amidine compound which can serve as an active ingredient of a highly safe herbicide which shows a reliable effect at a low dose. Also disclosed is a herbicide comprising the compound as an active ingredient. An amidi...
|
|
WO/2007/013694A1 |
A compound represented by the general formula (I): (I) wherein each symbol is as defined in the description. The compound is excellent in the effect of decreasing the blood glucose level and the blood lipid level, and therefore is useful...
|
|
WO/2007/006409A2 |
The invention relates to a herbicide-safener combination containing (A) one or several compounds of formula (I) or the salts thereof, wherein R1, R2, R3, R4, and R5 represent different radicals, n represents 1 or 2, X represents H or C1-...
|
|
WO/2007/003294A1 |
The invention relates to compounds of general formula (I) and the salts thereof, to methods for the production thereof, and to the use of the same as herbicides and plant growth regulators, especially as herbicides for the selective cont...
|
|
WO/2007/005531A2 |
Non-nucleoside inhibitors of HIV-I reverse transcriptase are described. Such inhibitors may be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds des...
|
|
WO/2007/003295A2 |
The invention relates to a method for producing 3-arylmethylthio- and 3-heteroarylmethylthio-4,5-dihydro-isoxazoline derivatives of general formula (I), by means of a one-pot reaction wherein corresponding arylmethyl and heteroarylmethyl...
|
|
WO/2007/002214A2 |
There is provided a series of substituted acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2. R3, R4 and R5 as defined herein, their pharmaceutical compositions and methods of ...
|
|
WO/2007/002557A1 |
The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and meth...
|
|
WO/2007/002220A2 |
There is provided a series of substituted acyl guanidines of Formula (Ik) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R2, R3, R4, R5, R25, R26 and R27 as defined herein, their pharmaceutical compositions and...
|
|
WO/2007/002172A2 |
Described are novel protease inhibitors and methods for using said protease inhibitors in the treatment of human immunodeficiency virus (HIV) infection.
|
|
WO/2006/136245A1 |
The invention relates to substituted spiro-compounds, to methods for producing the same, to medicaments comprising said compounds and to the use of said compounds for producing medicaments.
|
|
WO/2006/131296A1 |
The invention relates to substituted N-benzo[d]isoxazol-3-yl-amine derivatives of formula (I) wherein R1,R2,R3,R4 and R5 are defined as in patent claim 1. The invention also relates to the use of said compounds for producing medicaments.
|
|
WO/2006/132197A1 |
Disclosed is a compound useful as a type I 11β hydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: wherein R1 represents a cycloalkyl which may be substituted, a cycloalkenyl which may be substituted or the li...
|
|
WO/2006/131336A1 |
Disclosed are polycyclic compounds of formula I which are useful as sphingosine-1 -phosphate (S 1 P) receptor ligands, particularly as immunosuppressants.
|
|
WO2006076575B1 |
The present invention provides compounds of Formula: (I); or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, and ring B are as defined herein. The compounds of Formul...
|
|
WO/2006/127871A2 |
The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.
|
|
WO/2006/125370A1 |
The present invention discloses a kind of aromatic ether compounds of general formula (I), in which the definitions of substituents are illuminated as description. The aromatic ether compounds of the present invention have broad spectrum...
|
|
WO/2006/126751A1 |
The present invention relates to new diaryl-isoxazole derivatives, and pharmaceutical compositions containing the same as an effective ingredient for the prevention and the treatment of cancers. Diaryl-isoxazole derivatives of the presen...
|
|
WO/2006/126514A1 |
A compound represented by the formula (I), a pharmaceutically acceptable salt of the compound, or a solvate of the compound or salt: (I) wherein Y represents a group represented by the formula (II) below, provided that Y is not a phenyl ...
|
|
WO/2006/122949A1 |
Malononitrile compounds of formula (I) wherein R1 is H, (halo)alkyl, (halo)alkenyl, or (halo)alkynyl; R2 is H1 CN, (halo)alkyl, (halo)alkenyl, (halo)alkynyl, (halo)cycloalkyl, or (halo)alkoxy; R3 and R4 are H, (halo)alkyl, (halo)alkenyl,...
|
|
WO/2006/122799A1 |
The substituted benzo(d)isoxazol-3-yl-amine compounds of general formula (I) are suitable for treating pains and have an excellent affinity to vanilloid receptor subtype 1 (VR1/TRPV1 receptor) and are therefore especially useful in the p...
|
|
WO/2006/122800A1 |
Disclosed are substituted benzo[d]isoxazol-3-yl amine compounds of general formula (I), which are suitable for the treatment of pain while being provided with an excellent affinity to the KCNQ2/3 K+ channel and thus being suitable for th...
|
|
WO/2006/116615A1 |
The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep.
|
|
WO/2006/111321A1 |
The invention relates to azole derivatives of formula (I) whose meanings are given in a description and to salts thereof which can be pharmaceutically used in the form of drags.
|
|
WO/2006/106778A1 |
Disclosed is a breast cancer resistant protein (BCRP/ABCG2) inhibitor. A BCRP inhibitor comprising an acrylonitrile derivative represented by the general formula (1) or a salt thereof as the active ingredient: (1) (E or Z) wherein one of...
|
|
WO/2006/105127A2 |
Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: formula (I), wherein the variables are as defined herein.
|
|
WO/2006/100479A1 |
Methods of making heteroaromatic compounds comprising a 5- membered ring, and dihydro forms thereof, by a metal catalysed 5-endo-cyclisation of alkynes (acetylenes) are disclosed. The methods involve the use of a catalyst comprising a si...
|
|
WO/2006/101052A1 |
Disclosed is an acetylene derivative represented by the general formula (1A), (1B) or (1C) below, a prodrug thereof or a pharmacologically acceptable salt of such an acetylene derivative or prodrug. Also disclosed is an HSP90 inhibitor w...
|
|
WO/2006/096564A1 |
Fused aromatic compounds of Formula (I) are PPAR gamma agonists or partial agonists and are useful in the treatment or control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyc...
|
|
WO/2006/090052A1 |
The invention concerns novel products of formula (I), wherein: A1 and A2 represent CH or N; X represents Cra or N; Y represents CRb or N; R1, R2, R3 and R4 identical or different represent in particular hydrogen, halogen, cyano, nitro, t...
|
|
WO/2006/090234A1 |
The present invention relates to certain heterocyclic derivatives of formula (I) , in particular isoxazoline and isothiazoline derivatives as cell adhesion inhibitors. The compounds of this invention can be useful, for inhibition and pre...
|
|
WO/2006/089177A2 |
The invention relates to compounds of structural formula (I); or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/o...
|
|
WO/2006/084688A1 |
Compounds of the formula (I): Wherein R1, R2, X and N are as defined in the specification; E is N, CH; A1 and A" are terminal groups as defined in the specification. The compounds have utility as HIV-I protease inhibitors.
|
|
WO/2006/085212A2 |
The present invention relates to isoxazoline derivatives of fprmula (I), which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asth...
|
|
WO/2006/083271A2 |
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...
|
|
WO/2006/076706A1 |
The present invention provides novel cinnamide compounds of formula (I) useful as inhibitors of raf -protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and use thereof in th...
|
|
WO/2006/074244A2 |
The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzy...
|
|
WO/2006/074330A2 |
The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzym...
|
|
WO/2006/069685A1 |
The invention relates to compounds of formula (I), where A1, A2, R1, R2, R3, R4, R5 and Y have the meanings given in the description, methods and intermediates for production thereof and use thereof for the prevention of pests.
|
|
WO/2006/071184A1 |
Compounds of Formula I: wherein R1, R2, R3, R4, R5 Ar1 and X are as described in the specification, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in the...
|
|
WO/2006/069656A1 |
The invention relates to compounds of the formula (I) in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as ...
|
|
WO/2006/068092A1 |
The invention provides a process for producing (4,5-dihydro- isoxazol-3-yl)thiocarboxamidine salts easily and safely in a high yield which is freed from the disadvantages of the prior art. Specifically, a process for producing (4,5-dihyd...
|
|
WO/2006/067472A1 |
A compound of the formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R2, R3, R4 and R5 are independently selected from the group consisting of H, C1-7 alkoxy, amino, halo or hydroxy; n is...
|
|
WO/2006/062249A1 |
A compound represented by the formula (1): (1) wherein A, B, R1, L1, R2, L2, L3, Y, L4, R3 and X are defined in the present specification, a tautomer of said compound, a prodrug or pharmaceutically acceptable salt thereof or a solvated p...
|
|
WO/2006/062093A1 |
An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substi...
|
|
WO/2006/059149A1 |
Compounds of formula (I) are potent and selective 5-HT2A antagonists, useful in treatment of a variety of adverse conditions of the CNS.
|
|
WO/2006/059744A1 |
A compound represented by the general formula (II) below or a salt thereof is used as an activator of peroxisome proliferator activated receptor &dgr . (In the formula, B1 represents an alkylene having 2-4 carbon atoms; X21 and Y21 respe...
|
